temozolomide
Pronunciation: /tɛˈmoʊzəloʊmaɪd/
Also written as: TMZ
An oral alkylating chemotherapy agent that is standard-of-care for glioblastoma treatment.
Full Definition
Temozolomide (TMZ) is an oral alkylating chemotherapy agent that serves as the backbone of glioblastoma treatment. It can cross the blood-brain barrier and is administered both concurrently with radiation therapy and as adjuvant maintenance therapy. The drug's efficacy is significantly influenced by MGMT methylation status, and editors must be familiar with standard dosing schedules, common side effects, and resistance mechanisms. Proper editorial handling includes accurate drug naming, dosing information, and appropriate context regarding its role in combination therapies.
Usage
Usage note: Spell out on first reference before using TMZ; always include dose and schedule when clinically relevant.
In Context
- "Standard temozolomide dosing consists of 75 mg/m² daily during radiation followed by six cycles of adjuvant therapy." — Treatment protocol document
- "Patients receiving temozolomide should be monitored for lymphopenia and thrombocytopenia." — Safety monitoring guidelines